Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey

Overview

Journal Clin Med Insights Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2014 Jun 27

PMID 24966712

Citations 15

Authors

Maria Cappello

Claudia Randazzo

Ivana Bravata

Anna Licata

Sergio Peralta

Antonio Craxi

Piero Luigi Almasio

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Inflammatory bowel diseases (IBD) are frequently associated with altered liver function tests (LFTs). The causal relationship between abnormal LFTs and IBD is unclear. The aim of our study was to evaluate the prevalence and etiology of LFTs abnormalities and their association with clinical variables in a cohort of IBD patients followed up in a single center.

Materials And Methods: A retrospective review was undertaken of all consecutive IBD in- and outpatients routinely followed up at a single referral center. Clinical and demographic parameters were recorded. Subjects were excluded if they had a previous diagnosis of chronic liver disease. LFT abnormality was defined as an increase in aspartate aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), or total bilirubin.

Results: A cohort of 335 patients (179 males, mean age 46.0 ± 15.6 years) was analyzed. Abnormal LFTs were detected in 70 patients (20.9%). In most cases, the alterations were mild and spontaneously returned to normal values in about 60% of patients. Patients with abnormal LFTs were less frequently on treatment with aminosalicylates (22.8 vs. 36.6%, P = 0.04). The most frequent cause for transient abnormal LFTs was drug-induced cholestasis (34.1%), whereas fatty liver was the most frequent cause of persistent liver damage (65.4%). A cholestatic pattern was found in 60.0% of patients and was mainly related to older age, longer duration of disease, and hypertension.

Conclusions: The prevalence of LFT abnormalities is relatively high in IBD patients, but the development of severe liver injury is exceptional. Moreover, most alterations of LFTs are mild and spontaneously return to normal values. Drug-induced hepatotoxicity and fatty liver are the most relevant causes of abnormal LFTs in patients with IBD.

Citing Articles

A hepatocyte-specific transcriptional program driven by Rela and Stat3 exacerbates experimental colitis in mice by modulating bile synthesis.

Jyotsna , Sarkar B, Yadav M, Deka A, Markandey M, Sanyal P Elife. 2024; 12.

PMID: 39137024 PMC: 11321761. DOI: 10.7554/eLife.93273.

Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis.

Stratmann K, Aydolmus S, Gu W, Heling D, Spengler U, Terjung B Front Med (Lausanne). 2024; 10:1273797.

PMID: 38249970 PMC: 10796802. DOI: 10.3389/fmed.2023.1273797.

root and its major components ameliorate inflammation and altered gut microbial diversity and compositions in DSS-induced colitis.

Erdenebileg S, Son Y, Kim M, Oidovsambuu S, Cha K, Kwon J Integr Med Res. 2023; 12(4):100998.

PMID: 38024289 PMC: 10630121. DOI: 10.1016/j.imr.2023.100998.

Characterizing the pre-clinical phase of inflammatory bowel disease.

Vestergaard M, Allin K, Poulsen G, Lee J, Jess T Cell Rep Med. 2023; 4(11):101263.

PMID: 37939713 PMC: 10694632. DOI: 10.1016/j.xcrm.2023.101263.

Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study.

Nagata T, Funakoshi S, Morihara D, Shakado S, Yokoyama K, Takata K Intest Res. 2023; 21(4):471-480.

PMID: 37559192 PMC: 10626015. DOI: 10.5217/ir.2023.00035.

References

Navaneethan U, Shen B . Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(9):1598-619. DOI: 10.1002/ibd.21219. View

Mendes F, Levy C, Enders F, Loftus Jr E, Angulo P, Lindor K . Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 102(2):344-50. DOI: 10.1111/j.1572-0241.2006.00947.x. View

Shepherd H, Selby W, Chapman R, Nolan D, Barbatis C, Mcgee J . Ulcerative colitis and persistent liver dysfunction. Q J Med. 1983; 52(208):503-13. View

Schrumpf E, Fausa O, Elgjo K, Kolmannskog F . Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis. 1988; 8(3):201-9. DOI: 10.1055/s-2008-1040541. View

Fournier M, Klein J, Minuk G, Bernstein C . Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010; 105(7):1620-6. DOI: 10.1038/ajg.2010.21. View

Lorusso D, Leo S, Mossa A, Misciagna G, Guerra V . Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum. 1990; 33(9):791-4. DOI: 10.1007/BF02052328. View

Gisbert J, Luna M, Gonzalez-Lama Y, Pousa I, Velasco M, Moreno-Otero R . Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13(9):1106-14. DOI: 10.1002/ibd.20160. View

Schrumpf E, Elgjo K, Fausa O, GJONE E, Kolmannskog F, Ritland S . Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol. 1980; 15(6):689-97. DOI: 10.3109/00365528009181516. View

Lapidus A, Bangstad M, Astrom M, Muhrbeck O . The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol. 1999; 94(5):1261-6. DOI: 10.1111/j.1572-0241.1999.01076.x. View

10.

Bouhnik Y, Lemann M, Mary J, Scemama G, Tai R, Matuchansky C . Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347(8996):215-9. DOI: 10.1016/s0140-6736(96)90402-x. View

11.

Perrett A, Higgins G, Johnston H, Massarella G, TRUELOVE S, Wright R . The liver in ulcerative colitis. Q J Med. 1971; 40(158):211-38. DOI: 10.1093/oxfordjournals.qjmed.a067266. View

12.

Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S . Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol. 1997; 32(2):153-61. DOI: 10.3109/00365529709000186. View

13.

Hartleb M, Biernat L, Kochel A . Drug-induced liver damage -- a three-year study of patients from one gastroenterological department. Med Sci Monit. 2002; 8(4):CR292-6. View

14.

Perrett A, Higgins G, Johnston H, Massarella G, TRUELOVE S, Wrigth R . The liver in Crohn's disease. Q J Med. 1971; 40(158):187-209. DOI: 10.1093/oxfordjournals.qjmed.a067265. View

15.

Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G . Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2006; 11(46):7227-36. PMC: 4725142. DOI: 10.3748/wjg.v11.i46.7227. View

16.

Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F . Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003; 36(5):417-20. DOI: 10.1097/00004836-200305000-00012. View

17.

Marteau P, Nelet F, Le Lu M, Devaux C . Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996; 10(6):949-56. DOI: 10.1046/j.1365-2036.1996.92264000.x. View

18.

Saich R, Chapman R . Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3):331-7. PMC: 2679122. DOI: 10.3748/wjg.14.331. View

19.

De Fazio C, Torgano G, de Franchis R, Meucci G, Arrigoni M, Vecchi M . Detection of liver involvement in inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res. 1992; 21(4):314-7. DOI: 10.1007/BF02591669. View

20.

Wewer V, Gluud C, Schlichting P, Burcharth F, Binder V . Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1991; 26(1):97-102. DOI: 10.3109/00365529108996489. View